Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
2(29%)
Results Posted
50%(2 trials)

Phase Distribution

Ph phase_3
3
43%
Ph phase_2
2
29%
Ph phase_1
1
14%

Phase Distribution

1

Early Stage

2

Mid Stage

3

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
2(33.3%)
Phase 3Large-scale testing
3(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

7

all time

Status Distribution
Active(2)
Completed(4)
Other(1)

Detailed Status

Completed4
Active, not recruiting1
Recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
2
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (16.7%)
Phase 22 (33.3%)
Phase 33 (50.0%)

Trials by Status

active_not_recruiting114%
recruiting114%
completed457%
unknown114%

Recent Activity

2 active trials
Showing 5 of 7
recruitingphase_3

Donidalorsen Treatment in Children With Hereditary Angioedema

NCT07298447
active_not_recruitingphase_3

A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)

NCT05392114
unknown

Donidalorsen Expanded Access Program for Patients With Hereditary Angioedema

NCT06415448
completedphase_2

An Extension Study of Donidalorsen (IONIS-PKK-LRx) in Participants With Hereditary Angioedema

NCT04307381
completedphase_3

OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in Participants With Hereditary Angioedema (HAE)

NCT05139810
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT07298447Phase 3

Donidalorsen Treatment in Children With Hereditary Angioedema

Recruiting
NCT05392114Phase 3

A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)

Active Not Recruiting
NCT06415448

Donidalorsen Expanded Access Program for Patients With Hereditary Angioedema

Unknown
NCT04307381Phase 2

An Extension Study of Donidalorsen (IONIS-PKK-LRx) in Participants With Hereditary Angioedema

Completed
NCT05139810Phase 3

OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in Participants With Hereditary Angioedema (HAE)

Completed
NCT04030598Phase 2

A Study to Assess the Clinical Efficacy of Donidalorsen (Also Known as IONIS-PKK-LRx and ISIS 721744) in Participants With Hereditary Angioedema

Completed
NCT03263507Phase 1

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Donidalorsen (IONIS-PKK-LRx) Administered Subcutaneously to Healthy Volunteers

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7